(12). 133
The Beijing genetic group was predominant among both pulmonary and extrapulmonary 134 isolates (Table 1) , however, Beijing isolates were significantly more frequent among XPTB 135 patients (82.19%, n=60) than among PTB patients (66.67%, n=48, p=0.03721). A large 136 proportion of M.tuberculosis Beijing isolates (45.37%, n=59) belonged to B0/W148 sub-cluster. 137
The Beijing B0/W148 group was equally represented in PTB vs. were mono-resistant; 9 (12.33%) were poly-resistant; 44 (60.27%) were MDR and 5 (6.85%) 160
were XDR. Seven out of 72 pulmonary isolates (9.72%) were susceptible to all drugs; 2 (2.7%) 161 were mono-resistant; 9 -resistant to several drugs, but not MDR; 30 isolates (41.67%) -MDR 162 and 24 (33.33%) were XDR. The prevalence of XDR phenotype was almost 5-fold higher in 163 PTB than was observed in XPTB cases (33% XDR in PTB vs. 6.8% XDR in XPTB; p= 164 6.133*10 -05 ; Table 2 ). The majority of bacterial isolates in Beijing cluster were resistant to at 165 least one drug. 166
Over 80% of M.tuberculosis isolates in Beijing cluster had MDR (n=62) and XDR 167 (n=25). Only 9 out of 108 isolates were susceptible to all drugs ( 
SM-resistance (16). We identified only two KM-resistant and 3 susceptible isolates with 181
mutations in the region upstream whiB7 and all of these mutants were resistant to SM. isolates with unknown ETH susceptibility data. Mutation in ethR gene (A70T) was detected only 207 in one ETH-resistant isolate, while mutations in ethA-ethR intergenic region (7 bp upstream ethA 208 or 69 bp upstream ethR start-codons) was detected in 9 isolates and only three of them were 209
ETH-resistant. 210
We compared mutations, associated with M.tuberculosis drug resistance, detected in our 211 study with a list of mutations that are widely used in molecular-genetic tests for M.tuberculosis 212 identification and drug resistance prediction: HAIN GenoType MTBDRplus and GenoType 213
MTBDRsl v 1.0 and v 2.0. The majority of mutations associated with INH-resistance that were 214 detected in our study could be detected by HAIN assay, however mutation in -34 position 215 upstream fabG-inhA operon is not included in HAIN catalogue may be due to relatively rare 216 occurrence (2 isolates in our dataset). Detection of mutations associated with RIF-resistance 217 using HAIN assay would also allow to identify most of RIF-resistant isolates in our dataset, 218 however Q432K mutation in rpoB gene detected in one RIF-resistant strain and might be related 219 with RIF-resistance. Mutations associated with EMB-resistance detected by HAIN diagnostic 220 assay are represented by M306V and M306I substitutions only. In our study M306V was the 221 most frequent mutation (n=20), M306I substitution were identified in 5 genomes, while 38 222 
M.tuberculosis isolates that had mutations in
embB region between codons 296 and 497 that 223 could not be detected by HAIN system. Mutations in embA promoter region that are not 224 represented in HAIN test-system were detected in 14 EMB-resistant isolates. It should be noted 225 that mutations in embB gene and embA promoter associated with EMB-resistance often detected 226 among EMB-susceptible isolates. For instance, mutation M306V in embB gene was detected in 227 20 EMB-resistant and 9 EMB-susceptible isolates. Mutations associated with resistance to 228 aminoglycosides and peptide antibiotics are represented in HAIN test by 3 mutations in rrs gene, 229 associated with
TB/HIV co-infection 241
Bacterial isolates were collected from 120 HIV-negative patients and 25 HIV-infected 242 patients. We observed a higher rate of generalized TB among HIV-infected individuals (Table 4 ) 243 (p= 6.579*10 -05 ). XPTB was significantly more frequent among HIV-positive patients compared 244
to patients with PTB (Table 4 ; p=0.000998). Thus, HIV-infection increases the probability of TB 245 generalization or development of active XPTB. XPTB development was significantly higheramong patients infected with HIV carrying the Beijing-unclustered strain of M.tuberculosis 247 (p=0.068) ( Table 5) . A similar XPTB excess was apparent among patients carrying the Beijing 248 B0/W148 strain (p= 0.0013) ( Table 5 ). Other genetic groups with HIV co-infection did not make 249 a significant impact on pulmonary or extrapulmonary TB development (Table 5) . 250
Discussion 251
Our study is devoted to the comparative analysis of M.tuberculosis isolates obtained from 252 patients with different clinical features of the disease -pulmonary and extrapulmonary TB. Our 253 previous analysis of M.tuberculosis isolates from patients with tuberculous spondylitis showed 254 that this group of bacterial strains is characterized by low genetic diversity and high prevalence 255
of Beijing isolates (82% of strains belonged to Beijing clade) (3). Prevalence of Beijing genetic 256
group among extrapulmonary M.tuberculosis isolates compared to pulmonary ones was also 257 reported in a recent study, which identified Beijing in 75% of the extrapulmonary M.tuberculosis 258
cases (19). Our current study showed that extrapulmonary M.tuberculosis isolates belong to 259
Beijing genetic group (82.2%) more often than pulmonary (66.7%). Despite there was a higher 260 It was shown that Beijing A and CAO isolates are significantly more often identified in 273 extrapulmonary TB cases, while isolates from principal genetic lineage 4.3 were mostly 274 identified in patients with pulmonary TB (Table 1) . Association of specific genetic clades and 275 sub-clades of M.tuberculosis strains with TB diagnosis, shown on our dataset, is an interesting 276 fact which suggests some specific molecular signatures in different M.tuberculosis genetic 277 groups that can make an impact on active TB disease localization at least in Russian population 278 of TB patients. 279
Analysis of mutations, associated with susceptibility to first and second line TB drugs 280 arevealed that relatively high proportion of INH-, RIF-, SM-and OFL-resistant isolates had 281 standard SNVs predictive of drug-resistance. However, some SNVs, associated with resistance 282 to TB drugs cannot be unequivocally interpreted. For example, the proportion of EMB-resistant 283 isolates with mutations in embB gene between codones 296 and 497 and embC-embA intergenic 284 region were identified in 94.29% of EMB-resistant isolates, however over 40% of EMB 285 susceptible isolates carried the same mutations. Similar situation was revealed with mutations, 286 associated with KM-resistance in eis and whiB7 promoter regions -42.5% of KM-resistant and 287
22.4% of KM-susceptible isolates carried mutations in these regions (ST3). This observation 288
might be related with the fact that mutations can be responsible for the development of high and 289 low levels of drug resistance, while in our study we did not have data on minimum inhibitory 290 concentration. M.tuberculosis isolates from our dataset were checked for mutations in pncA and 291 rpsA genes that were known to be involved in development of resistance to PZA (17, 25). Only 4 292 PZA-resistant isolates carried mutations in rpsA gene, but the majority of PZA-resistant isolates 293 had mutations in pncA gene mentioned in previously published catalog of mutations associated 294 with susceptibility to PZA (17). Despite most of obtained data were consistent with previously 295 published data, in PZA-resistant strains we detected few mutations, that were mentioned as 296 associated with susceptibility to PZA and there were several PZA-susceptible isolates, that 297 carried mutations associated with PZA-resistance according to Yadon et al. data . This fact mayindicate either that these mutations are not involved into the development of PZA resistance, or 299 their influence on resistance to higher doses of the drug that were analyzed in our research. The funders had no role in study design, data collection and analysis, decision to publish, or 334 preparation of the manuscript. 335 
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